Author

C. V. Leiton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

C.-H. Pan· 3 shared K. R. Shroyer· 3 shared L. F. Escobar-Hoyos· 3 shared L. Roa-Pena· 2 shared R. Tseng· 2 shared S. Chowdhury· 2 shared A. Biankin· 1 shared B. Chen· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C.-H. Pan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Disassembly of embryonic keratin filaments promotes pancreatic cancer

R. R. Kawalerski, M. Torrente Goncalves, C.-H. Pan, R. Tseng, L. Roa-Pena, C. V. Leiton, L. A. Torre-Healy, T. Boyle, S. Chowdhury, N. T. Snider, K. R. Shroyer, L. F. Escobar-Hoyos

This study shows that phosphorylation of K17 promotes pancreatic cancer metastasis and shorter survival by disassembling keratin filaments and enabling nuclear translocation.

bioRxiv · Aug 27, 2022 · PreprintCancer Biology

Targeting keratin 17-mediated reprogramming of de novo pyrimidine biosynthesis to overcome chemoresistance in pancreatic cancer

C.-H. Pan, N. Chaika, R. Tseng, M. A. Siraj, B. Chen, K. L. Donnelly, M. Horowitz, C. V. Leiton, S. Chowdhury, L. Roa-Pena, L. Oblein, N. Marchenko, P. K. Singh, K. R. Shroyer, L. F. Escobar-Hoyos

This study identifies K17-mediated pyrimidine biosynthesis as a mechanism of chemoresistance in PDAC and shows that targeting DHODH with Brequinar enhances the efficacy of chemotherapy.

bioRxiv · Aug 24, 2022Cancer Biology

An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C. V. Leiton, J. D. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K. R. Shroyer

This study identifies K17 as a biomarker for PDAC and shows that PPT, a microtubule inhibitor, is more effective against K17-expressing PDAC cells when combined with Gemcitabine.

bioRxiv · Oct 11, 2019Cancer Biology